Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reffron
- Development stage
- Unknown
- Lead developer
- Sunways India
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Reffron is a vitreo-retinal protector and dietary supplement marketed by Sunways India. It is formulated as an oral tablet containing a combination of saffron extract (Crocus sativus), resveratrol, lutein, zeaxanthin, vitamins (C, E, and B2), and minerals (zinc and copper). Reffron is used to support eye health and manage degenerative ocular conditions such as diabetic retinopathy and age-related macular degeneration (AMD). The ingredients work synergistically to provide antioxidant protection, reduce oxidative stress in retinal tissues, support microcirculation, and protect against blue light-induced damage.
- Brand names
- Reffron
Beyond the preview
Go deeper on Reffron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reffron.